The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2015
At a glance
- Drugs Erlotinib (Primary) ; Rifampicin
- Indications Non-small cell lung cancer; Pancreatic cancer
- Focus Pharmacokinetics; Therapeutic Use
- 11 Dec 2015 New trial record